 Abdelrahman Fouda
Concepts (180)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Diseases | 5 | 2025 | 53 | 2.440 |
Why?
| | Reperfusion Injury | 6 | 2024 | 73 | 2.370 |
Why?
| | Arginase | 8 | 2023 | 35 | 2.350 |
Why?
| | Retina | 6 | 2024 | 60 | 2.240 |
Why?
| | Neuroprotective Agents | 5 | 2021 | 103 | 1.910 |
Why?
| | Stroke | 10 | 2022 | 527 | 1.750 |
Why?
| | Receptor, Angiotensin, Type 2 | 4 | 2022 | 23 | 1.520 |
Why?
| | Retinal Neovascularization | 2 | 2022 | 4 | 1.360 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 4 | 2019 | 44 | 1.220 |
Why?
| | Renin-Angiotensin System | 3 | 2019 | 58 | 1.200 |
Why?
| | Phagocytosis | 2 | 2025 | 54 | 1.140 |
Why?
| | Mice, Inbred C57BL | 8 | 2024 | 1888 | 1.050 |
Why?
| | Thiophenes | 5 | 2022 | 45 | 1.020 |
Why?
| | Mice, Knockout | 7 | 2024 | 903 | 0.980 |
Why?
| | Sulfonamides | 5 | 2022 | 137 | 0.950 |
Why?
| | Eye | 1 | 2025 | 28 | 0.950 |
Why?
| | Eye Diseases | 1 | 2025 | 33 | 0.930 |
Why?
| | Animals | 27 | 2025 | 13485 | 0.920 |
Why?
| | Infarction, Middle Cerebral Artery | 6 | 2022 | 42 | 0.890 |
Why?
| | Aqueous Humor | 1 | 2024 | 10 | 0.880 |
Why?
| | Retinal Artery Occlusion | 1 | 2024 | 11 | 0.870 |
Why?
| | Drug Delivery Systems | 2 | 2025 | 148 | 0.870 |
Why?
| | Nanoparticles | 1 | 2025 | 131 | 0.860 |
Why?
| | Histone Deacetylases | 1 | 2024 | 50 | 0.840 |
Why?
| | Macrophages | 3 | 2025 | 357 | 0.820 |
Why?
| | Retinopathy of Prematurity | 1 | 2022 | 16 | 0.760 |
Why?
| | Ischemia | 2 | 2023 | 150 | 0.740 |
Why?
| | Proteomics | 1 | 2024 | 332 | 0.720 |
Why?
| | Minocycline | 2 | 2017 | 15 | 0.660 |
Why?
| | Brain Injuries | 1 | 2021 | 158 | 0.650 |
Why?
| | Brain | 6 | 2021 | 1337 | 0.620 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 73 | 0.620 |
Why?
| | Endothelins | 1 | 2019 | 17 | 0.610 |
Why?
| | Angiogenesis Inducing Agents | 2 | 2016 | 7 | 0.600 |
Why?
| | Rats, Wistar | 8 | 2022 | 223 | 0.580 |
Why?
| | Cerebrovascular Circulation | 1 | 2019 | 126 | 0.560 |
Why?
| | Mice | 10 | 2024 | 5899 | 0.560 |
Why?
| | Cognition Disorders | 1 | 2019 | 213 | 0.540 |
Why?
| | Endothelial Cells | 6 | 2023 | 283 | 0.510 |
Why?
| | Interleukin-10 | 1 | 2017 | 81 | 0.510 |
Why?
| | Cerebral Hemorrhage | 1 | 2017 | 102 | 0.500 |
Why?
| | Brain-Derived Neurotrophic Factor | 2 | 2016 | 39 | 0.500 |
Why?
| | Disease Models, Animal | 10 | 2023 | 1483 | 0.490 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2016 | 7 | 0.490 |
Why?
| | Cognition | 1 | 2019 | 363 | 0.480 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2022 | 136 | 0.420 |
Why?
| | Inflammation | 1 | 2018 | 649 | 0.420 |
Why?
| | Myeloid Cells | 2 | 2024 | 42 | 0.420 |
Why?
| | Optic Nerve Injuries | 2 | 2023 | 8 | 0.390 |
Why?
| | Brain Ischemia | 4 | 2021 | 168 | 0.390 |
Why?
| | Neovascularization, Physiologic | 3 | 2022 | 86 | 0.380 |
Why?
| | Tetrazoles | 4 | 2018 | 41 | 0.380 |
Why?
| | Benzimidazoles | 4 | 2018 | 50 | 0.370 |
Why?
| | Rats | 7 | 2022 | 3228 | 0.370 |
Why?
| | Polyethylene Glycols | 2 | 2022 | 93 | 0.360 |
Why?
| | Recovery of Function | 6 | 2019 | 201 | 0.340 |
Why?
| | Blood-Brain Barrier | 2 | 2021 | 50 | 0.330 |
Why?
| | Endothelium, Vascular | 4 | 2022 | 263 | 0.320 |
Why?
| | Neovascularization, Pathologic | 3 | 2022 | 158 | 0.300 |
Why?
| | Male | 14 | 2024 | 26874 | 0.290 |
Why?
| | Apoptosis | 3 | 2025 | 1120 | 0.290 |
Why?
| | Humans | 15 | 2025 | 52441 | 0.290 |
Why?
| | Oxygen | 2 | 2022 | 332 | 0.260 |
Why?
| | Diabetes Mellitus | 3 | 2016 | 318 | 0.260 |
Why?
| | Administration, Ophthalmic | 1 | 2025 | 4 | 0.240 |
Why?
| | Ornithine | 2 | 2023 | 18 | 0.240 |
Why?
| | Thromboembolism | 2 | 2018 | 48 | 0.240 |
Why?
| | Nanotechnology | 1 | 2025 | 31 | 0.240 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2024 | 10 | 0.220 |
Why?
| | Vitreous Body | 1 | 2024 | 18 | 0.220 |
Why?
| | Paracentesis | 1 | 2024 | 13 | 0.220 |
Why?
| | Eye Proteins | 1 | 2024 | 16 | 0.220 |
Why?
| | Biphenyl Compounds | 4 | 2018 | 32 | 0.210 |
Why?
| | Ornithine Decarboxylase | 1 | 2023 | 12 | 0.210 |
Why?
| | Microglia | 1 | 2025 | 139 | 0.210 |
Why?
| | Vitrectomy | 1 | 2024 | 61 | 0.210 |
Why?
| | Imidazoles | 2 | 2022 | 114 | 0.200 |
Why?
| | Mass Spectrometry | 1 | 2024 | 294 | 0.200 |
Why?
| | Blood-Retinal Barrier | 1 | 2021 | 6 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 38 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2023 | 390 | 0.180 |
Why?
| | Copper | 1 | 2022 | 47 | 0.180 |
Why?
| | Behavior, Animal | 2 | 2019 | 190 | 0.170 |
Why?
| | Signal Transduction | 5 | 2022 | 1724 | 0.170 |
Why?
| | Cytokines | 1 | 2023 | 622 | 0.170 |
Why?
| | Recombinant Proteins | 1 | 2021 | 490 | 0.160 |
Why?
| | Motor Activity | 2 | 2019 | 227 | 0.160 |
Why?
| | Nitric Oxide | 2 | 2018 | 238 | 0.160 |
Why?
| | Cell Survival | 1 | 2021 | 598 | 0.160 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 415 | 0.160 |
Why?
| | Receptors, Endothelin | 1 | 2019 | 6 | 0.150 |
Why?
| | Receptors, Angiotensin | 1 | 2019 | 11 | 0.150 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2018 | 62 | 0.150 |
Why?
| | Nitric Oxide Synthase | 1 | 2018 | 72 | 0.140 |
Why?
| | Neurons | 1 | 2021 | 442 | 0.140 |
Why?
| | Forecasting | 1 | 2019 | 151 | 0.140 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2018 | 83 | 0.140 |
Why?
| | Vascular Stiffness | 1 | 2017 | 24 | 0.140 |
Why?
| | Diabetic Retinopathy | 1 | 2018 | 43 | 0.140 |
Why?
| | Mitochondria | 1 | 2021 | 420 | 0.130 |
Why?
| | Administration, Intravenous | 1 | 2017 | 73 | 0.130 |
Why?
| | Tissue Plasminogen Activator | 1 | 2018 | 108 | 0.130 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 131 | 0.130 |
Why?
| | Vascular Diseases | 1 | 2017 | 75 | 0.130 |
Why?
| | Acute Disease | 1 | 2017 | 384 | 0.120 |
Why?
| | Injections, Intraventricular | 1 | 2016 | 13 | 0.120 |
Why?
| | Angiotensins | 1 | 2016 | 12 | 0.120 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2016 | 56 | 0.120 |
Why?
| | RNA, Small Interfering | 1 | 2016 | 217 | 0.120 |
Why?
| | Infant, Newborn | 1 | 2022 | 2871 | 0.110 |
Why?
| | Alzheimer Disease | 1 | 2019 | 356 | 0.110 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 135 | 0.110 |
Why?
| | Neuronal Plasticity | 1 | 2014 | 57 | 0.110 |
Why?
| | Thioredoxins | 1 | 2014 | 26 | 0.110 |
Why?
| | Female | 4 | 2024 | 28277 | 0.100 |
Why?
| | Cerebral Cortex | 1 | 2014 | 197 | 0.100 |
Why?
| | Carrier Proteins | 1 | 2014 | 312 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2017 | 570 | 0.090 |
Why?
| | Hypertension | 1 | 2016 | 560 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2019 | 1583 | 0.080 |
Why?
| | Aged | 1 | 2024 | 10242 | 0.080 |
Why?
| | Blood Pressure | 3 | 2018 | 525 | 0.080 |
Why?
| | Cattle | 2 | 2022 | 197 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2017 | 5508 | 0.080 |
Why?
| | Obesity | 1 | 2017 | 1176 | 0.080 |
Why?
| | Middle Aged | 1 | 2024 | 13133 | 0.070 |
Why?
| | Time Factors | 3 | 2019 | 2987 | 0.060 |
Why?
| | Random Allocation | 2 | 2018 | 286 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2015 | 186 | 0.050 |
Why?
| | Nerve Crush | 1 | 2023 | 2 | 0.050 |
Why?
| | Glutamates | 1 | 2023 | 22 | 0.050 |
Why?
| | Optic Nerve | 1 | 2023 | 39 | 0.050 |
Why?
| | Cysteine | 1 | 2022 | 51 | 0.050 |
Why?
| | Mitochondrial Dynamics | 1 | 2021 | 22 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2022 | 102 | 0.040 |
Why?
| | Oxidative Stress | 2 | 2017 | 805 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2022 | 236 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2022 | 327 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2021 | 566 | 0.040 |
Why?
| | Cell Line | 1 | 2022 | 1020 | 0.040 |
Why?
| | Microvessels | 1 | 2019 | 35 | 0.040 |
Why?
| | Sensory Gating | 1 | 2018 | 1 | 0.040 |
Why?
| | Rats, Inbred SHR | 1 | 2018 | 37 | 0.040 |
Why?
| | PPAR gamma | 1 | 2019 | 72 | 0.040 |
Why?
| | Cell Hypoxia | 1 | 2018 | 82 | 0.040 |
Why?
| | Locomotion | 1 | 2018 | 80 | 0.040 |
Why?
| | Amyloid beta-Peptides | 1 | 2018 | 73 | 0.030 |
Why?
| | Dietary Sucrose | 1 | 2017 | 14 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2018 | 214 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2018 | 129 | 0.030 |
Why?
| | Vasodilation | 1 | 2017 | 99 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 198 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 735 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2018 | 726 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 725 | 0.030 |
Why?
| | Hippocampus | 1 | 2018 | 231 | 0.030 |
Why?
| | Arginine | 1 | 2017 | 183 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2017 | 230 | 0.030 |
Why?
| | Hydro-Lyases | 1 | 2015 | 2 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2017 | 378 | 0.030 |
Why?
| | Brain Infarction | 1 | 2015 | 12 | 0.030 |
Why?
| | Cerebrovascular Trauma | 1 | 2015 | 11 | 0.030 |
Why?
| | Diabetes Complications | 1 | 2016 | 124 | 0.030 |
Why?
| | Matrix Metalloproteinases | 1 | 2015 | 47 | 0.030 |
Why?
| | Insulin | 1 | 2017 | 485 | 0.030 |
Why?
| | Blood Glucose | 1 | 2017 | 483 | 0.030 |
Why?
| | Middle Cerebral Artery | 1 | 2015 | 33 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2015 | 127 | 0.030 |
Why?
| | Phenotype | 1 | 2017 | 792 | 0.030 |
Why?
| | Cell Communication | 1 | 2015 | 74 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 525 | 0.030 |
Why?
| | Muscle Strength | 1 | 2015 | 132 | 0.030 |
Why?
| | Cell Movement | 1 | 2015 | 271 | 0.030 |
Why?
| | Comorbidity | 1 | 2016 | 637 | 0.030 |
Why?
| | Stilbenes | 1 | 2014 | 58 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2015 | 217 | 0.030 |
Why?
| | Pyridines | 1 | 2015 | 137 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2014 | 223 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 461 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 1013 | 0.020 |
Why?
|
|
Fouda's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|